Facebook
Twitter
LinkedIn
ForwardManagement of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients. Clinicians must understand the treatment evolution and guidelines for when to administer two-, three- or four-drug regimens as initial therapy in context of the patient's therapeutic and disease history. When the disease relapses, selecting the optimal therapies is a challenge. Recently, FDA expanded indications for use of CAR T-cell therapies in earlier lines of therapy in the relapsed/refractory setting. With the ever-expanding treatment options, there are numerous factors to consider when selecting therapies for patients with MM as there is no standardized approach. Aggressive disease warrants initiation of a new therapy combination or a new class of therapy, and disease related factors are as important as patient-specific factors. Education on the available agents and understanding how to individualize treatment to improve outcomes of patients with MM is important.
The optimal approach to management of smoldering multiple myeloma (SMM) remains a debated topic. A risk-stratification system has been developed and revised to identify patients with SMM at the highest risk of progression, primarily based on tumor burden and elimination of normal plasma cells by the malignant clone. To optimize patient outcomes, clinicians need to understand the risks and benefits of early intervention for SMM based on risk stratification and the importance of enrolling patients in clinical trials examining early intervention.
Target Audience
This program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this program, participants should be able to:
- Outline risk factors for progression of smoldering multiple myeloma to symptomatic multiple myeloma.
- Select appropriate evidence-based strategies for management of patients with smoldering multiple myeloma taking individual patient-risk into consideration.
- Review available therapeutic options for newly diagnosed and relapsed/refractory multiple myeloma.
- Select optimal treatment for newly diagnosed and relapsed/refractory multiple myeloma taking disease-related and patient-specific characteristics into consideration.
Christopher R. D’Angelo, MD
Fred & Pamela Buffett Cancer Center
Jens Hillengass, MD, PhD
Roswell Park Comprehensive Cancer Center
Shaji K. Kumar, MD
Mayo Clinic Comprehensive Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Christopher R. D’Angelo, MD
AbbVie, Inc.: Consulting Fee
BeiGene: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Grant/Research Support
Curis, Inc.: Consulting Fee; Grant/Research Support
Fate Therapeutics: Grant/Research Support
GenMab: Consulting Fee; Grant/Research Support
Ono Pharma: Consulting Fee
Jens Hillengass, MD, PhD
Amgen Inc.: Honoraria
Angitia Biopharmaceuticals: Scientific Advisor
Axess Network: Scientific Advisor
BeiGene: Honoraria
Curio Science: Honoraria
Janssen Pharmaceutica Products, LP: Scientific Advisor
Prothena: Scientific Advisor
Regeneron Pharmaceuticals: Scientific Advisor
Sebia Inc.: Scientific Advisor
Shaji K. Kumar, MD (also a member of the Congress Planning Committee)
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb: Grant/Research Support; Scientific Advisor
CARsgen Therapeutics: Grant/Research Support
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Moderna, Inc.: Consulting Fee
Oricell Therapeutics: Grant/Research Support
Pfizer Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor
Congress Planning Committee Disclosures
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Consulting Fee
PharmaEssentia USA Corporation: Consulting Fee
Regeneron Pharmaceuticals: Equity Interest/Stock Options
Bernard L. Marini, PharmD, BCOP
Servier: Consulting Fee
MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Consulting Fee; Honoraria
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 2.25 contact hours, 2.25 of which are pharmacotherapeutic contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 2.25 contact hours (0.225 CEUs) of continuing education credit. UAN: JA4008196-0000-24-127-H01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 CME credits. Approval is valid until December 1, 2025. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 2.25 AAPA Category 1 CME credit
- 2.25 ACPE contact hours
- 2.25 AMA PRA Category 1 Credit™
- 2.25 ANCC contact hours
- 2.25 ANCC Pharmacology Contact Hours
- 2.25 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing